<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PHENYTOIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PHENYTOIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tonic-clonic seizures</span>,
                <span class="indication">Focal seizures</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 3&#8211;4 mg/kg daily, alternatively 150&#8211;300 mg once daily, alternatively 150&#8211;300 mg daily in 2 divided doses, then increased to 200&#8211;500 mg daily, to be taken preferably with or after food, dose to be increased gradually as necessary (with plasma-phenytoin concentration monitoring), exceptionally, higher doses may be used.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                Initially 1.5&#8211;2.5 mg/kg twice daily, then adjusted according to response to 2.5&#8211;5 mg/kg twice daily (max. per dose 7.5 mg/kg twice daily), dose also adjusted according to plasma-phenytoin concentration; maximum 300 mg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 75&#8211;150 mg twice daily, then adjusted according to response to 150&#8211;200 mg twice daily (max. per dose 300 mg twice daily), dose also adjusted according to plasma-phenytoin concentration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Status epilepticus</span>,
                <span class="indication">Acute symptomatic seizures associated with head trauma or neurosurgery</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Loading dose 20 mg/kg (max. per dose 2 g), to be given at a rate not exceeding 1 mg/kg/minute (max. 50 mg per minute), to be given with blood pressure and ECG monitoring, then (by intravenous infusion or by slow intravenous injection or by mouth) maintenance 100 mg every 6&#8211;8 hours adjusted according to plasma-concentration monitoring, to be given with blood pressure and ECG monitoring, adjusted according to plasma-phenytoin concentration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Status epilepticus</span>,
                <span class="indication">Acute symptomatic seizures associated with trauma or neurosurgery</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                Loading dose 20 mg/kg, then 2.5&#8211;5 mg/kg twice daily, to be given with blood pressure and ECG monitoring.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Loading dose 20 mg/kg, then up to 100 mg 3&#8211;4 times a day, to be given with blood pressure and ECG monitoring.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Preparations containing phenytoin sodium are <b>not</b> bioequivalent to those containing phenytoin base (such as <i>Epanutin Infatabs</i>
            <tm tmtype="reg"/> and <i>Epanutin</i>
            <tm tmtype="reg"/> suspension); 100&#8239;mg of phenytoin sodium is approximately equivalent in therapeutic effect to 92&#8239;mg phenytoin base. The dose is the same for all phenytoin products when initiating therapy, however, if switching between these products the difference in phenytoin content may be clinically significant. Care is needed when making changes between formulations and plasma-phenytoin concentration monitoring is recommended.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce dose to avoid toxicity.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Acne, anorexia, coarsening of facial appearance, constipation, dizziness, drowsiness, gingival hypertrophy and tenderness (maintain good oral hygiene), headache, hirsutism, insomnia, nausea, paraesthesia, rash, transient nervousness, tremor, vomiting,
              </p>
              <p>
                <strong>rare:</strong> Leucopenia, aplastic anaemia, blood disorders, dyskinesia, hepatotoxicity, lupus erythematosus, lymphadenopathy, megaloblastic anaemia, osteomalacia, peripheral neuropathy, polyarteritis nodosa, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis,
              </p>
              <p>
                <strong>notKnown:</strong> Hypersensitivity syndrome, interstitial nephritis, pneumonitis, polyarthropathy, suicidal ideation,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> alterations in respiratory function, arrhythmias, cardiovascular collapse, cardiovascular depression (particularly if injection too rapid), CNS depression (particularly if injection too rapid), hypotension, respiratory arrest,
              </p>
              <p>
                <strong>notKnown:</strong> purple glove syndrome, tonic seizures,
              </p>
        
            <section class="advice">
                <h3>Rash</h3>
              <p>Discontinue; if mild re-introduce cautiously but discontinue immediately if recurrence.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Reduce rate of administration if bradycardia or hypotension occurs.</p>
            </section>
            <section class="advice">
              <p>Phenytoin may cause coarsening of the facial appearance, acne, hirsutism, and gingival hyperplasia and so may be particularly undesirable in adolescent patients.</p>
            </section>
            <section class="advice">
                <h3>Hepatotoxicity</h3>
              <p>Discontinue immediately and do not re-administer.</p>
            </section>
        
            <section class="overdosageInformation">
              <p>Symptoms of phenytoin toxicity include nystagmus, diplopia, slurred speech, ataxia, confusion, and hyperglycaemia.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Before and after administration flush intravenous line with Sodium Chloride 0.9%.</p><p>For <i>intravenous injection</i>, give into a large vein at rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute).</p><p>For <i>intravenous infusion</i>, dilute to a concentration not exceeding 10&#8239;mg/mL with Sodium Chloride 0.9% and give into a large vein through an in-line filter (0.22&#8211;0.50&#8239;micron) at a rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute); complete administration within 1 hour of preparation.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Epanutin</i>
            <tm tmtype="reg"/>), give intermittently in Sodium chloride 0.9%. Flush intravenous line with Sodium chloride 0.9% before and after infusion; dilute in 50&#8211;100&#8239;mL infusion fluid (final concentration not to exceed 10&#8239;mg/mL) and give into a large vein through an in-line filter (0.22&#8211;0.50&#8239;micron) at a rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute); complete administration within 1 hour of preparation.</p><p>To avoid local venous irritation each injection or infusion should be preceded and followed by an injection of sterile physiological saline through the same needle or catheter.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Blood or skin disorders</h3>
              <p>Patients or their carers should be told how to recognise signs of blood or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative).</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Phenytoin for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures">www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Enteral feeding (interrupt feeding for 2 hours before and after dose; more frequent monitoring may be necessary)
          </li>
        </ul>
        <ul>
          <li>
              <strong>With intravenous use:</strong>
            heart failure
          </li>
          <li>
              <strong>With intravenous use:</strong>
            hypotension
          </li>
          <li>
              <strong>With intravenous use:</strong>
            injection solutions alkaline (irritant to tissues)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            respiratory depression
          </li>
          <li>
              <strong>With intravenous use:</strong>
            resuscitation facilities must be available
          </li>
        </ul>
        <ul>
          <li>
            <p>Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.</p>
          </li>
          <li>
            <p>Intramuscular phenytoin should not be used (absorption is slow and erratic).</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">In adults</h3>
              <p>The usual total plasma-phenytoin concentration for optimum response is 10&#8211;20&#8239;mg/litre (or 40&#8211;80&#8239;micromol/ litre). In pregnancy, the elderly, and certain disease states where protein binding may be reduced, careful interpretation of total plasma-phenytoin concentration is necessary; it may be more appropriate to measure free plasma-phenytoin concentration.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">In children</h3>
              <p>Therapeutic plasma-phenytoin concentrations reduced in first 3 months of life because of reduced protein binding.</p><p>Trough plasma concentration for optimum response: neonate&#8211;3 months, 6&#8211;15&#8239;mg/litre (25&#8211;60&#8239;micromol/ litre); child 3 months&#8211;18 years, 10&#8211;20&#8239;mg/litre (40&#8211;80&#8239;micromol/litre).</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Manufacturer recommends blood counts (but evidence of practical value uncertain).</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Monitor ECG and blood pressure.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Licensed for use in children (age range not specified by manufacturer).</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Phenytoin doses in BNF publications may differ from those in product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
                <h3>Switching between formulations</h3>
              <p>Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer's product.</p>
            </section>
      </section>




      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <p>HLAB* 1502 allele in individuals of Han Chinese or Thai origin&#8212;avoid unless essential (increased risk of Stevens- Johnson syndrome).</p>
            </section>
      </section>




      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>Cross-sensitivity reported with carbamazepine.</p><p>Antiepileptic hypersensitivity syndrome associated with phenytoin. See under <xref format="dita" href="#PHP78230" type="bookmark" namespace="/treatment-summaries/epilepsy">Epilepsy</xref> for more information.</p>
            </section>
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PHENYTOIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP76217"><a href="../medicinalForm/PHP76217.html" data-target="#PHP76217" data-action="load">Tablet</a></div>
            <div id="PHP76238"><a href="../medicinalForm/PHP76238.html" data-target="#PHP76238" data-action="load">Chewable tablet</a></div>
            <div id="PHP76224"><a href="../medicinalForm/PHP76224.html" data-target="#PHP76224" data-action="load">Capsule</a></div>
            <div id="PHP76245"><a href="../medicinalForm/PHP76245.html" data-target="#PHP76245" data-action="load">Oral suspension</a></div>
            <div id="PHP76231"><a href="../medicinalForm/PHP76231.html" data-target="#PHP76231" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
